2018 № 8 Analysis of death rates related to hemoblastosis in the population of St. Petersburg for the period of 1990–2016 and the forecast up to 2026
The authors have analyzed the level and dynamics of mortality in the population of St. Petersburg from malignant neoplasms of lymphoid, hematopoietic and related tissues in the period from 1990 to 2016 and made a forecast for the period of up to 2026. It was established that in 2016 St. Petersburg ranked 3rd in terms of the level of mortality from hemoblastoses among the constituent entities of the Russian Federation. The mortality of men exceeded the mortality of women. The period under study was found to have a death rate decrease by 46.3%, which is due to the introduction of highly effective therapeutic and diagnostic technologies into clinical practice. According to the forecast, the probable reduction in the death rate by 2026 compared to 2016 is 21.1%. As the cost of therapeutic and diagnostic technologies is growing, the work on the enhancement of the results of treatment of hemoblastoses and further reduction of mortality rates from these diseases needs to be done in a comprehensive manner, at the state level
2019 № 1 Analysis of hemoblastosis morbidity rate of saint petersburg population for 1990–2016 period and forecast till 2026
Level and dynamics of hematological malignancies morbidity of Saint Petersburg population were analyzed for 1990–2016 period and forecast till 2026 was given. It was found that in 2016 Saint Petersburg held the 1st place in hemoblastosis incidence among territories of the Russian Federation. Morbidity of men increased morbidity of women. The highest morbidity levels were detected in 70–79 age group. The increase of hemoblastosis incidence was followed up, the highest increase rate was noticed among people of working age. The increase of hemoblastosis prevalence (general morbidity) was observed. According to the forecast if the detected tendency towards the increase remains in 2026 the incidence rate will increase by 8.6% if compared with 2016 and will make 21.4 morbid events per 100 thousand of population; the general morbidity rate will increase by 44.4% and will make 130.4 morbid events per 100 thousand of population. The data received give evidence of the increase of the population’s need in expert oncohaematological treatment, necessity in the increase of its availability to the population and more efficient use of existing resources.